Earnings of consumer food company General Mills (GIS) declined in the first quarter, but to a lower extent than predicted by analysts. Sales increased but missed estimates narrowly, triggering a stock selloff.
Net income attributable to shareholders increased to $392.3 million or $0.65 per share in the first quarter from $404.7 million or $0.69 per share a year earlier. Earnings, adjusted for recurring items, were $0.71 per share, in line with the first quarter of 2018. Analysts were looking for a faster decline. Profitability was impacted by a 160-bps fall in gross margin due to cost inflation and charges related to the acquisition of Blue Buffalo.
Net sales rose 9% annually to $4.09 billion during the first quarter, when organic sales gained modestly. The top-line was broadly in line with Wall Street expectations. A 2% decline in North America retail was more than offset by a 3.6% growth in Convenience Stores and Foodservice. Europe & Australia and Asia & Latin America registered 1.8% growth each.
“We drove organic net sales growth for the fourth consecutive quarter. The Blue Buffalo transition is progressing well, and we continue to expect double-digit top and bottom-line growth for that business this year, excluding acquisition-related charges,” said General Mills CEO Jeff Harmening.
A 2% decline in North America retail was more than offset by a 3.6% growth in Convenience Stores and Foodservice
The company, which makes ready-to-eat snacks like Cheerios cereal and Yoplait yogurt, reiterated the outlook for its full-year 2019 adjusted earnings between flat and down 3% year-on-year. It continues to expect full-year net sales to rise in the range of 9% to 10% and sees organic sales between flat and up 1%.
General Mills shares witnessed a 19% fall so far this year, underperforming the market. Currently, the stock is in the recovery mode, and closed the last trading session slightly higher. Following the announcement, the stock dropped nearly 4% in premarket trading Tuesday.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
